Theradiag, a company specializing in theranostics and in vitro diagnostics, has partnered with Hospira for the supply of LISA-TRACKER’s CE-marked infliximab monitoring kit.
 
Hospira will provide LISA TRACKER’s infliximab assays and anti-infliximab antibodies assays kits in Europe, Canada and Australia to give clinicians and patients high level biological information regarding the treatment with the biosimilar of infliximab (Remicade). Hospira has selected Theradiag as its exclusive provider of monitoring tools.
 
Theradiag will supply Hospira with LISA TRACKER monitoring kits and will also ensure installation and training in labs, as well as provide information and follow-up with clinicians on behalf of Hospira. LISA TRACKER’s infliximab kits have been validated for use with Inflectra.
 
“This partnership marks a significant change in how pharmaceutical companies view theranostics and is a formidable opportunity to promote the monitoring of biotherapies. For the first time, a pharmaceutical company will be pairing our monitoring kits with their treatments. This will build greater awareness within the medical and patients’ community regarding the benefits of biotherapy monitoring, which improve patient care while cutting healthcare spending,” said Michel Finance, chief executive officer of Theradiag.
 
Hospira commercializes Inflectra (a biologic equivalent to Remicade). It’s the first biosimilar monoclonal antibody to be approved by the EMA, and is indicated for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriasis and psoriatic arthritis.